Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $1,275 - $2,119
-118 Reduced 17.82%
544 $7,000
Q4 2023

Feb 14, 2024

BUY
$8.84 - $18.7 $2,545 - $5,385
288 Added 77.01%
662 $9,000
Q3 2023

Nov 21, 2023

BUY
$11.42 - $20.82 $4,271 - $7,786
374 New
374 $4,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.